AEON Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 07/22/23 | FY 07/21/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $12.2M | $13.6M | — | — | — |
| Research and development | $4.1M | $14.2M | — | — | — |
| Operating expenses | $12.8M | $73.0M | — | — | — |
| Operating income | -$12.8M | $73.0M | — | — | — |
| Pretax income | -$39.2M | $42.0M | — | — | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$39.2M | $42.0M | — | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $3.0M | $13,000 | $5.2M | — | $31.2M |
| Current assets | $3.4M | $1.6M | $6.2M | — | — |
| Total assets | $5.6M | $3.1M | $6.8M | — | — |
| Current liabilities | $6.9M | $14.1M | $13.0M | — | — |
| Total liabilities | $60.6M | $31.7M | $159.9M | — | — |
| Stockholders' equity | -$55.0M | -$28.6M | -$153.0M | $167.1M | -$310.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$17.3M | -$20.3M | — | — | — |
| Depreciation and amortization | $78,000 | $97,000 | — | — | — |
| Stock-based compensation | $5.3M | $6.2M | — | — | — |
| Capital expenditure | $4,000 | — | — | — | — |
| Free cash flow | -$17.3M | — | — | — | — |
Shares outstanding 26.3M · Free float 23.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.